The study emerges from a pressing need to understand the psychosocial challenges faced by older adults afflicted with HIV/AIDS, a population segment often neglected in both research and care priorities. Globally, advancements in antiretroviral therapy have extended the lifespan of individuals living with HIV, but aging with the chronic infection introduces complex psychological stressors. The researchers meticulously examine how depressive symptoms manifest among this ageing cohort in Mbarara, a locale emblematic of sub-Saharan Africa’s HIV burden. Their findings suggest that the psychological toll of living with HIV into older age remains profoundly underestimated and inadequately addressed.

Central to the investigation is the exploration of counseling services as a potential mitigating factor against depression. The authors articulate that counseling, often sidelined in resource-limited settings, holds promise in alleviating the mental health burden associated with chronic illness. Through a nuanced analysis, the study portrays counseling not merely as emotional support but as an integral component of holistic HIV care. It advocates for integrating mental health services into routine HIV treatment protocols, underscoring that physical health advancements alone cannot guarantee improved quality of life for this demographic.

The research methodology applied by the team incorporates validated psychometric tools to assess depressive symptomatology among participants living with HIV/AIDS aged 50 and above. By employing standardized scales, the study ensures robust and replicable quantification of mental health status, thereby augmenting the reliability of its conclusions. Moreover, the inclusion criteria and data collection settings reflect a realistic snapshot of the community health context in Mbarara, lending authenticity and relevance to the outcomes.

An important revelation from the study is the high prevalence of depressive symptoms detected among the older adult participants, which mirrors trends observed in high-resource settings but within a distinctly different cultural and healthcare environment. This finding challenges assumptions that aging with HIV in low-income contexts follows less complicated psychological trajectories. Instead, it spotlights the compounded challenges presented by social stigma, economic hardship, and limited access to comprehensive healthcare — factors intricately intertwined with mental health outcomes.

Recognizing depression in older adults with HIV is a formidable challenge, exacerbated by overlapping somatic symptoms of aging, medication side effects, and the chronic viral illness itself. The research team illustrates how misdiagnosis or underdiagnosis of depression can lead to suboptimal care and diminished adherence to antiretroviral therapy. Importantly, untreated depression is known to accelerate HIV progression and increase mortality risk, underscoring the critical need for mental health interventions.

The researchers further contextualize the findings within the broader health systems limitations of Uganda and similar regions. Mental health services are often underfunded and staffed inadequately, with few specialized professionals available to address the complex needs of older HIV-positive individuals. This systemic gap necessitates innovative approaches to counseling delivery, potentially leveraging community health workers and task-shifting strategies to overcome human resource constraints.

Culturally sensitive counseling, as highlighted in the study, is paramount. The authors note that effective mental health interventions must resonate with local beliefs and practices to overcome barriers related to stigma and mistrust. The study’s qualitative insights reveal that when counseling respects cultural norms and offers empathetic engagement, it significantly improves patients’ emotional resilience and coping strategies.

Notably, the study emphasizes the ripple effects of depressive symptom reduction: enhanced medication adherence, improved social functioning, and better overall wellbeing. These multidimensional benefits suggest that investment in counseling is not merely a mental health imperative but a cornerstone in advancing comprehensive HIV care paradigms. By framing mental health support as central to HIV treatment efficacy, the research advocates for policy shifts in public health programming.

In examining policy implications, the study urges stakeholders to allocate resources strategically towards integrating mental health assessments and counseling in HIV clinics. Training healthcare providers to screen for depression and provide basic psychosocial support could revolutionize care outcomes. Furthermore, partnerships with non-governmental organizations and global health initiatives could facilitate the scaling of such integrated care models.

Looking ahead, the authors call for longitudinal studies to track the long-term impact of counseling on depression trajectories and HIV disease progression in older populations. They also highlight the need to investigate the potential genetic, neurological, and immunological mechanisms linking HIV, aging, and depression — complex intersections that remain underexplored yet vital for targeted therapeutic development.

This study holds critical implications beyond Mbarara. As the global population ages and the HIV epidemic persists, understanding and addressing the mental health needs of older adults with HIV/AIDS becomes an international priority. The research underscores that without robust mental health support, the gains achieved through medical treatment risk being undermined — transforming HIV from a chronic manageable disease into an insidious driver of psychological decline.

In a world increasingly driven by biomedical advances, this research reconnects the narrative to the human experience, highlighting the indispensable role of psychological well-being in living with chronic disease. As societies grapple with aging populations and chronic illnesses, integrating counseling into healthcare emerges as a pivotal strategy to foster dignity, hope, and improved health outcomes.

Ultimately, the work by Amanyire and colleagues contributes an essential perspective to the discourse on HIV/AIDS care: that to confront this epidemic holistically, mental health must be appreciated not as an adjunct but as a fundamental element of survival and quality of life. Their findings advocate for a future where psychosocial interventions are seamlessly interwoven into the fabric of public health responses, especially in areas confronting the dual challenges of infectious disease and resource scarcity.

The evolving field of HIV/AIDS treatment must now expand its lens to encapsulate mental health with equal vigor, recognizing that counseling can be a lifeline, fostering resilience amid adversity. This transformative viewpoint holds promise for millions worldwide, particularly in the global south, shining a beacon of hope for holistic healing in the face of HIV’s enduring shadow.

Subject of Research: Counseling and depressive symptoms in older adults living with HIV/AIDS in Mbarara, Uganda

Article Title: Counselling and depressive symptoms in older adults with HIV/AIDS in Mbarara, Uganda

Article References:
Amanyire, J.M., Aheisibwe, I., Asiimwe, R. et al. Counselling and depressive symptoms in older adults with HIV/AIDS in Mbarara, Uganda. BMC Psychol 13, 840 (2025). https://doi.org/10.1186/s40359-025-03178-x

Image Credits: AI Generated

In clinical practice, the management of HIV demands not only viral suppression but also the mitigation of treatment-related side effects. Neuropsychiatric adverse events—encompassing symptoms such as depression, insomnia, and aggressive mood—pose substantial risks to patient quality of life and retention in care. This Ethiopian study provides critical insights by quantifying the burden of such adverse effects among people living with HIV (PLHIV) newly prescribed DTG-based regimens under real-life conditions, a topic previously underexplored in low-resource environments.

The investigation encompassed 620 participants from multiple healthcare centers throughout Ethiopia, capturing diverse demographic and clinical profiles. Researchers utilized structured questionnaires and patient interviews alongside review of medical records to obtain comprehensive data on sociodemographic variables, clinical status, and self-reported neuropsychiatric symptoms. Analytical strategies including both bivariate and multivariate models identified strong associations between certain patient characteristics and the likelihood of experiencing neuropsychiatric adverse events.

Notably, female patients were found to have a significantly higher adjusted odds ratio (AOR) for NPAEs at 1.72 compared to males, suggesting sex-related biological or psychosocial vulnerabilities in DTG tolerability. Age also emerged as a potent factor, with individuals aged between 47 and 54 years exhibiting an AOR of 3.8, and those aged 55 to 75 years showing an AOR of 1.27. This age-related susceptibility may reflect underlying neurological changes or cumulative exposure to antiretroviral therapy influencing adverse event development.

Occupational status was instrumental in the risk profile, as unemployment correlated with an increased AOR of 1.35 for neuropsychiatric symptoms. Additionally, physical activity levels played a crucial role—patients with minimal or no physical activity had markedly heightened odds (AOR of 2.4 and 3.6, respectively), emphasizing the protective role of an active lifestyle in mitigating these side effects. These findings underscore the multifactorial nature of adverse events, integrating biomedical and lifestyle dimensions.

Duration of therapy was similarly influential, with patients on DTG-based regimens for 6 to 12 months carrying a threefold increased risk (AOR = 3.35), and those between 13 to 24 months maintaining an elevated risk (AOR = 2.67). This temporal relationship suggests cumulative neurotoxicity or adaptive neuropsychiatric responses over time, warranting vigilant monitoring beyond initial treatment phases.

Disease progression as classified by the WHO clinical staging system surfaced as a robust correlate: patients in stages II through IV exhibited significantly higher odds of experiencing NPAEs—AORs ranging from 3.65 to 4.21, respectively. This association may be driven by systemic illness severity, immune activation, or CNS involvement exacerbating neuropsychiatric vulnerability during DTG therapy. Moreover, detectable viral load at treatment initiation was independently associated with an increased risk (AOR = 1.24), highlighting incomplete viral suppression as a determinant of poorer neuropsychiatric outcomes.

These findings raise pivotal concerns about the neuropsychiatric safety landscape of DTG in populations with advanced HIV disease and underscore the necessity of individualized patient monitoring frameworks. Early identification and management of neuropsychiatric adverse events could improve adherence rates, reduce regimen switching and discontinuation, and ultimately enhance long-term treatment success. Clinicians are urged to employ comprehensive screening tools, integrate psychosocial interventions, and promote physical activity as potential mitigating strategies.

The Ethiopian study’s implications extend to global HIV treatment programs, where scale-up of DTG regimens intersects with heterogeneous patient populations and limited psychiatric care resources. Tailored policies must prioritize patient subgroups identified as high-risk—older adults, women, unemployed individuals, and those with advanced disease—ensuring holistic care that addresses mental health alongside virological control. Future research should explore mechanistic pathways underlying these associations and evaluate interventional models in similar real-world settings.

From a pharmacological perspective, neuropsychiatric side effects likely arise from DTG’s central nervous system penetration and modulation of neurotransmitter systems, yet individual susceptibilities vary. Genetic, metabolic, and psychosocial parameters may modulate adverse reaction profiles, demanding integrative research approaches. Moreover, temporal patterns observed in the Ethiopian cohort raise questions about cumulative neurotoxicity, neuroinflammation, or drug-drug interactions influencing persistence or resolution of symptoms.

Overall, this rigorous multicenter investigation illuminates a critical aspect of HIV management through its nuanced examination of factors linked to neuropsychiatric adverse events in DTG-treated patients. Its evidence base empowers clinicians, public health experts, and policymakers to refine therapeutic strategies, bolster monitoring protocols, and enhance patient-centered care in resource-constrained environments confronting the contemporary challenges of HIV treatment.

As the global fight against HIV evolves, balancing potent antiretroviral efficacy with tolerability remains paramount. The Ethiopian experience offers valuable lessons for optimizing DTG implementation worldwide, reminding stakeholders that biomedical triumphs must be matched by attentiveness to neuropsychiatric health to achieve sustainable success in epidemic control.

Subject of Research: Neuropsychiatric adverse events and associated factors in people living with HIV initiating Dolutegravir-based antiretroviral therapy in Ethiopia.

Article Title: Patients reported neuropsychiatric adverse events and associated factors among PLHIV patients receiving DTG-based regimen antiretroviral therapy real-life clinical practice in Ethiopia: multi center cross-sectional study.

Article References:
Chanie, G.S., Belachew, E.A., Seid, A.M. et al. Patients reported neuropsychiatric adverse events and associated factors among PLHIV patients receiving DTG-based regimen antiretroviral therapy real-life clinical practice in Ethiopia: multi center cross-sectional study. BMC Psychiatry 25, 383 (2025). https://doi.org/10.1186/s12888-025-06820-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-06820-5